News & Updates

Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.

Greater intrinsic motivation for engaging in healthy lifestyle behaviours appears to promote long-term postpartum weight reduction and may be a promising target for interventions, suggests a study.

Gynaecologic oncology patients with better sleep efficiency in the days before a surgical procedure are more likely to have fewer postoperative complications and require lower doses of opioid pain medication upon hospital discharge, according to a study.

For hospitalized individuals initiating treatment for alcohol use disorder (AUD), oral naltrexone is equally efficacious as the extended-release injectable formulation in terms of reducing heavy drinking days, as shown in a study.

In adult patients with treatment-naive neovascular age-related macular degeneration (nAMD), the use of faricimab shows superior anatomic outcome compared with aflibercept during the head-to-head dosing phase, reports a study.

Regular physical activity appears to protect against lower extremity lymphedema in endometrial cancer survivors, as reported in a study.

A recent study has found that dexamethasone delivers better outcomes than methotrexate (MTX) and ranibizumab in patients with persistent or recurrent uveitic macular oedema through 24 weeks. In addition, side effects are manageable.

People with increased intramuscular fat infiltration (IMFI) in the thigh are at heightened risk of knee and hip osteoarthritis, according to a study.

Extracorporeal circulation, a technique for providing cardiopulmonary support during cardiac surgery, has a reduced risk of postoperative SAEs when delivered via a minimally invasive system rather than conventional technologies, according to results of the COMICS trial

In patients with resectable nonsmall cell lung cancer (NSCLC), adding perioperative durvalumab to neoadjuvant chemotherapy does not appear to have a detrimental impact on patient-reported health-related quality of life (QoL), functioning, or symptoms as compared with neoadjuvant chemotherapy alone, according to data from the phase III AEGEAN study.